GlassScriptPhysician profile
Amy M Chapman
NPI 1528289873
$2,586.31
in general payments reported to CMS, 2019-2025
24 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.12 · 2022: $265 · 2023: $605 · 2024: $663 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $483.98 | 2022-2025 | Slynd, Twirla |
| Exact Sciences Corporation | $213.08 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $201.57 | 2025 | Wegovy |
| Myriad Women'S Health, INC. | $195.06 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $192.94 | 2022-2025 | Aptima, Acessa Provu System |
| Abbvie INC. | $171.88 | 2022-2023 | Lo Loestrin Fe, Orilissa |
| Organon LLC | $158.31 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $140.03 | 2025 | |
| Evofem Biosciences, INC. | $122.97 | 2022-2025 | Phexxi, Solosec, Phexx |
| Pacira Pharmaceuticals Incorporated | $121.84 | 2024 | Exparel |
| Pfizer INC. | $110.59 | 2024-2025 | |
| Shield Therapeutics INC | $77.18 | 2023-2024 | Accrufer |
| Biogen, INC. | $53.41 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $49.71 | 2025 | Veozah |
| Therapeuticsmd, INC. | $44.92 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.60 | 2024 | Zepbound |
| Sumitomo Pharma America, INC. | $40.99 | 2024 | Myfembree |
| Minerva Surgical, INC | $34.13 | 2022-2025 | |
| Millicent US INC | $33.04 | 2023-2025 | Intrarosa, Femlyv |
| Aspira Women'S Health INC | $26.44 | 2024 | Ova1 |
| Lupin INC. | $24.12 | 2019 | |
| Coopersurgical, INC. | $16.78 | 2024 | Paragard T 380a |
| Davol INC. | $15.09 | 2022 | |
| Meditrina | $14.65 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.